Federal Realty Investment Trust
$14.95B- Market cap
- $10.12B
- Debt
- +$4.94B
- Cash
- −$107.42M
Capital structure 67% equity / 33% debt · EV / Revenue 11.69x · EV / EBITDA 19.50x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: FRT stock price vs Teva Pharmaceutical Industries Ltd: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at Teva Pharmaceutical Industries Ltd's multiple
Needs Teva Pharmaceutical Industries Ltd P/E.
Implied fair value · at FRT's multiple
Needs EPS (TTM), FRT P/E.
Engine logicFRTvalued onTeva Pharmaceutical Industries Ltd’smultiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: FRT FY 2025 (ended Dec 31, 2025) · Teva Pharmaceutical Industries Ltd Latest annual filing. Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 67% equity / 33% debt · EV / Revenue 11.69x · EV / EBITDA 19.50x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
FEDERAL REALTY INVESTMENT TRUST · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
TEVA PHARMACEUTICAL INDUSTRIES LTD · implied price per share
Reporting currency could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Teva Pharmaceutical Industries Ltd · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.52x
—
Net debt / EBITDA
Leverage against operating earnings
6.31x
—
Cash and equivalents
Liquid reserves on the balance sheet
$107.42M
—
Total debt
Interest-bearing obligations outstanding
$4.94B
—
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.